Add To Watchlist
Share URL
Organon & Co.
OGN: NYSELowest reading is at 5 out of 100. All scores are out of 100.
About The Company
CEO
Mr. Joseph T. Morrissey Jr.
Market Cap
3.61 Billion USD
Sector
Healthcare
Website
https://www.organon.comLast Update
27/09/2026, 09:07:04
Description
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Read More
Strongest readings
- ✔Price-to-earnings of 17.4 is below the market average of 19.6
Weakest readings
- ✘Debt is high at 11.49 times equity
- ✘Earnings have fallen this year (-70.89%)
- ✘Earnings and cashflow growth is weak (growth score 5 out of 100)
- ✘Financial health is poor (health score 27 out of 100)
- ✘The current price sits above estimated fair value (margin of safety -15.43%)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings (TTM) | 17.38x | 19.60x | |
| ✘ | Margin of safety (DCF) | -15.43% | 17.95% | |
| ✘ | Revenue growth (5y average) | -2.06% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.50% | 1.85% | |
| ✘ | Share count, per year | 0.47% | 0.00% | |
| Return on capital employed | N/A | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
48 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings | 17.38x | 19.60x | |
| ✔ | Free cashflow yield | 15.73% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 3.58x | — | ||
| ✘ | Margin of safety | -15.43% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 11.61 USD is below the current price of 13.73 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 38.2 USD ✔
Current Price: 13.7 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
5 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Revenue growth | -2.06% | 10.97% | |
| ✘ | Earnings growth | -32.27% | 14.48% | |
| ✘ | Cashflow growth | -17.22% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Revenue growth has slowed this year (-2.45% against a five year average of -2.06%)
- ✘Earnings growth has slowed this year (-70.89% against a five year average of -32.27%)
- ✔Free cashflow growth has improved this year
Health
27 / 100Balance sheet is stretched on several measures.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| Altman-Z score | N/A | 3.00 | ||
| ✔ | Piotroski score | 5.00 | 5.00 | |
| ✘ | Debt / equity | 11.49x | 0.80x | |
| ✔ | Current ratio | 1.82x | 1.00x | |
| Interest coverage | N/A | 2.50x | ||
| ✘ | Free cashflow / debt | 0.06x | 0.15x | |
| ✔ | Debt / capital | 0.92x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Dividend
55 / 100Covered, with limited headroom.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Dividend yield | 0.50% | 1.85% | |
| ✘ | Dividend growth | -70.37% | 0.00% | |
| ✔ | Payout ratio (earnings) | 8.61% | 40.00% | |
| ✔ | Payout ratio (cashflow) | 3.17% | 65.00% | |
| ✘ | Worst year, last 5 years | -70.65% | -2.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Dividend growth has been slowing recently
- ✘The dividend was cut within the last five years (worst year -70.65% per share)
- ✘Financial health puts the dividend at risk (health score 27 out of 100)
Management
53 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Return on equity | 24.87% | 15.00% | |
| Return on capital employed | N/A | 10.00% | ||
| Return on assets | 1.45% | — | ||
| Free cashflow return on capital | 5.14% | — | ||
| Return on capital, 5y change | N/A | 0.00% | ||
| ✘ | Share count, per year | 0.47% | 0.00% | |
| ✘ | Share count, recent | 1.20% | 0.00% | |
| Realized buyback return | N/A | 0.00% | ||
| ✘ | Goodwill erosion / equity | 70.08% | 2.00% | |
| Price volatility, 5 year | 44.76% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔New shares were issued while the value score was 48 out of 100
- ✘Return on equity of 24.87% is driven by debt rather than operations, because return on capital employed is only N/A
- ✘Dividends were raised while earnings fell (dividend 1.20% per year, earnings -32.27% per year)
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
OGN
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Organon & Co.
Currency
USD
Beta
1.518
Vol Avg
2715530
Ceo
Mr. Joseph T. Morrissey Jr.
Cik
0001821825
Cusip
Exchange
NYSE
Full Time Employees
10000
Industry
Drug Manufacturers - General
Sector
Healthcare
Ipo Date
Address
30 Hudson Street
City
Jersey City
State
NJ
Country
United States
Zip
07302
Phone
551 430 6900
Analysis Last Updated
27/09/2026, 09:07:04
Financial data compiled from SEC EDGAR filings and Yahoo Finance.